Clinical Trials Browser

Completed × tislelizumab × Gynecologic × Clear all

NCT05044871 2025-06-08

BRIGHT

Phase 2 Completed

Ovarian Neoplasms

NCT04693234 2025-04-27

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

178 enrolled 26 charts

Uterine Cervical Neoplasms